Hydrocortisonum Sf

Hydrocortisonum Sf is an oral medication that contains the corticosteroid hydrocortisone as its active ingredient. The product is marketed in the European Union and is supplied without a specified strength, indicating a generic formulation. As a glucocorticoid anti‑inflammatory agent, it is intended for systemic use under medical supervision and is classified in the H02AB02 ATC group. It is prescribed for conditions that require cortisol replacement or anti‑inflammatory therapy.

Hydrocortisonum Sf is used in clinical practice for several endocrine and inflammatory conditions where systemic glucocorticoid activity is required.

- Replacement therapy in primary or secondary adrenal insufficiency. - Management of acute adrenal crisis to restore cortisol levels. - Adjunct treatment of inflammatory or autoimmune disorders such as rheumatoid arthritis. - Control of severe allergic reactions, including angioedema and urticaria. - Short‑term therapy for flare‑ups of chronic inflammatory diseases. - Temporary supplementation during stress, surgery, or illness in patients on chronic glucocorticoid therapy. - Part of combination regimens for certain dermatologic conditions when oral therapy is preferred.

Oral hydrocortisone may be associated with a range of adverse reactions, which are generally categorized by frequency and clinical significance.

Common: - Mild gastrointestinal discomfort such as nausea or dyspepsia. - Transient increase in blood glucose levels, especially in diabetic patients. - Fluid retention leading to mild peripheral edema. - Mood changes including irritability or insomnia. - Skin thinning or easy bruising, particularly with prolonged use. - Headache or dizziness, often mild and transient. - Increased susceptibility to gastrointestinal ulcers, especially when combined with NSAIDs.

Serious: - Significant hyperglycemia or new‑onset diabetes mellitus. - Suppression of the hypothalamic‑pituitary‑adrenal axis causing adrenal insufficiency on abrupt discontinuation. - Severe infections due to immunosuppression, including opportunistic pathogens. - Osteoporosis or bone demineralization with long‑term therapy.

When prescribing Hydrocortisonum Sf, clinicians should evaluate several precautionary factors to minimize risks and ensure appropriate therapy.

- Assess baseline adrenal function and consider stress‑dosing in patients with known insufficiency. - Monitor blood glucose regularly in diabetic or pre‑diabetic individuals. - Evaluate for a history of hypertension, heart failure, or fluid overload before initiating therapy. - Use the lowest effective dose for the shortest duration to reduce the likelihood of systemic side effects. - Screen for active infections and avoid use in uncontrolled systemic infections. - Counsel patients on the signs of adrenal crisis and the need for medical attention if symptoms arise.

Hydrocortisonum Sf can alter the pharmacokinetics or pharmacodynamics of several concomitant medicines; awareness of these interactions helps optimize therapy.

Avoid: - Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce hydrocortisone plasma concentrations. - High‑dose non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase the risk of gastrointestinal ulceration when combined with glucocorticoids.

Use with caution: - Anticoagulants (e.g., warfarin) because glucocorticoids may enhance their anticoagulant effect. - Antidiabetic agents, as hydrocortisone can raise blood glucose and may require dose adjustments. - Vaccines, particularly live attenuated vaccines, due to potential immunosuppression. - Diuretics, which may exacerbate electrolyte disturbances such as hypokalemia.